ASLAN Pharmaceuticals (ASLN) Stock Forecast, Price Target & Predictions
ASLN Stock Forecast
ASLAN Pharmaceuticals stock forecast is as follows:
ASLAN Pharmaceuticals Financial Forecast
ASLAN Pharmaceuticals Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - | - | $3.00M |
| High Forecast | - | - | - | - | - | - | - | - | $3.00M |
| Low Forecast | - | - | - | - | - | - | - | - | $3.00M |
| # Analysts | - | - | - | - | - | - | - | 1 | - |
| Surprise % | - | - | - | - | - | - | - | - | - |
ASLAN Pharmaceuticals's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. ASLN's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
ASLAN Pharmaceuticals EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | 1 | - |
| EBITDA | - | - | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - | - | $600.00K |
| High Forecast | - | - | - | - | - | - | - | - | $600.00K |
| Low Forecast | - | - | - | - | - | - | - | - | $600.00K |
| Surprise % | - | - | - | - | - | - | - | - | - |
undefined analysts predict ASLN's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than ASLAN Pharmaceuticals's previous annual EBITDA (undefined) of $NaN.
ASLAN Pharmaceuticals Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | 1 | - |
| Net Income | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $-94.10M | $-89.62M | $-86.63M | $-82.15M | $-1.49M | $-2.99M | $-2.99M | $-47.80M | $-176.75M |
| High Forecast | $-94.10M | $-89.62M | $-86.63M | $-82.15M | $-1.49M | $-2.99M | $-2.83M | $-47.80M | $-176.75M |
| Low Forecast | $-94.10M | $-89.62M | $-86.63M | $-82.15M | $-1.49M | $-2.99M | $-3.14M | $-47.80M | $-176.75M |
| Surprise % | - | - | - | - | - | - | - | - | - |
ASLAN Pharmaceuticals's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. ASLN's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
ASLAN Pharmaceuticals SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | 1 | - |
| SG&A | - | - | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - | - | $4.15M |
| High Forecast | - | - | - | - | - | - | - | - | $4.15M |
| Low Forecast | - | - | - | - | - | - | - | - | $4.15M |
| Surprise % | - | - | - | - | - | - | - | - | - |
ASLAN Pharmaceuticals's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to ASLN last annual SG&A of $NaN (undefined).
ASLAN Pharmaceuticals EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | 1 | - |
| EPS | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $-5.04 | $-4.80 | $-4.64 | $-4.40 | $-0.08 | $-0.16 | $-0.16 | $-2.56 | $-9.47 |
| High Forecast | $-5.04 | $-4.80 | $-4.64 | $-4.40 | $-0.08 | $-0.16 | $-0.15 | $-2.56 | $-9.47 |
| Low Forecast | $-5.04 | $-4.80 | $-4.64 | $-4.40 | $-0.08 | $-0.16 | $-0.17 | $-2.56 | $-9.47 |
| Surprise % | - | - | - | - | - | - | - | - | - |
According to undefined Wall Street analysts, ASLAN Pharmaceuticals's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to ASLN previous annual EPS of $NaN (undefined).
ASLAN Pharmaceuticals Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| TIL | Instil Bio | $21.89 | $150.00 | 585.24% | Hold |
| AVTE | Aerovate Therapeutics | $2.60 | $13.00 | 400.00% | Hold |
| ANEB | Anebulo Pharmaceuticals | $1.62 | $6.00 | 270.37% | Buy |
| ANTX | AN2 Therapeutics | $1.36 | $5.00 | 267.65% | Buy |
| ACRV | Acrivon Therapeutics | $6.23 | $22.50 | 261.16% | Buy |
| GPCR | Structure Therapeutics | $28.25 | $99.00 | 250.44% | Buy |
| CMPX | Compass Therapeutics | $1.50 | $5.00 | 233.33% | Buy |
| CTMX | CytomX Therapeutics | $1.07 | $3.47 | 224.30% | Buy |
| LYRA | Lyra Therapeutics | $0.17 | $0.50 | 194.12% | Hold |
| CGEM | Cullinan Oncology | $12.27 | $34.00 | 177.10% | Buy |
| ADAG | Adagene | $1.94 | $5.00 | 157.73% | Buy |
| ASMB | Assembly Biosciences | $14.72 | $35.50 | 141.17% | Buy |
| MLYS | Mineralys Therapeutics | $12.80 | $30.00 | 134.38% | Buy |
| ERAS | Erasca | $2.57 | $6.00 | 133.46% | Buy |
| ACHL | Achilles Therapeutics | $1.14 | $2.00 | 75.44% | Buy |
| AGIO | Agios Pharmaceuticals | $34.19 | $53.50 | 56.48% | Buy |
| NAMS | NewAmsterdam Pharma | $25.95 | $39.33 | 51.56% | Buy |